http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020236925-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_19d19d9a2a4e79f808b24df5dd5b4bc5 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24121 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24151 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 |
| filingDate | 2020-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f87c45834317bbed3606aed768af3ad7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_703ab397b5fbcef5ddd4fbe772424a68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54b6b6ecd87da31f77fc032c170f2080 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e25bdb04f751c236d98a00f7b314ea0c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50d6ba43bb085a523bd7306a286f8817 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5ae4b703dac185f509c7c3f4020033f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fbf6128cea868306b3d92bcac4fed9c |
| publicationDate | 2020-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020236925-A1 |
| titleOfInvention | Mammalian cell for producing modified vaccinia ankara (mva) virus |
| abstract | The present invention relates to modified animal cells comprising a vaccinia virus gene encoding a protein having the activity of a vaccinia virus C12, C16, or C17 protein, and/or that is deficient in an activity that inhibits replication of MVA virus, such as ZAP activity. Also provided are altered MVA viruses that encode a protein comprising the activity of vaccinia virus C12 protein, a vaccinia virus C16 protein, or a vaccinia virus C17 protein, or that comprise a mutation in an MVA ORF encoding a decapping protein, such as ORF D9 or D10. Such viruses have an extended host range (i.e., (HRE MVA viruses). Also provided are methods of producing modified cells and HRE MVA viruses of the disclosure, as well as methods of producing progeny MVA virus in modified and unmodified animal cells. Also provided are methods of using MVA viruses of the disclosure to vaccinate individuals. |
| priorityDate | 2019-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 314.